BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/8/2026 11:12:35 AM | Browse: 7 | Download: 0
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Ca2+/calmodulin-dependent protein kinase II in heart failure and the role of sodium-glucose-cotransporter 2 inhibitors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yi-Fei Zhang, Wu-Xiao Yang and Xue-Wen Li |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 8217022047 |
|
| Corresponding Author |
Xue-Wen Li, Chief Physician, PhD, Professor, Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 99 Longcheng Street, Taiyuan 030032, Shanxi Province, China. xuewenli1010@126.com |
| Key Words |
Sodium-glucose cotransporter 2 inhibitor; Heart failure; Ca2+/calmodulin-dependent protein kinase II; Oxidative stress; Calcium homeostasis |
| Core Tip |
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have revolutionized the treatment of heart failure, but their direct molecular effects in cardiomyocytes, which express little sodium-glucose cotransporter-2, have not been fully described. This letter summarizes current evidence and presents a conceptual framework in which Ca2+/calmodulin-dependent protein kinase II is a central target. We hypothesize that many of the cardioprotective effects of SGLT2i are mediated by the dampening of Ca2+/calmodulin-dependent protein kinase II activity through synergistic modulation of ionic balance, relief of oxidative stress and inflammatory signaling suppression. Together, these processes may provide a unified explanation for the observed improvements in electrical stability, ventricular performance, and cardiac remodeling associated with SGLT2i treatment. |
| Citation |
Zhang YF, Yang WX, Li XW. Ca2+/calmodulin-dependent protein kinase II in heart failure and the role of sodium-glucose-cotransporter 2 inhibitors. World J Cardiol 2026; In press |
 |
Received |
|
2025-11-14 11:40 |
 |
Peer-Review Started |
|
2025-11-17 00:36 |
 |
First Decision by Editorial Office Director |
|
2025-11-26 08:19 |
 |
Return for Revision |
|
2025-11-26 08:19 |
 |
Revised |
|
2025-12-04 16:34 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-01-08 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-01-08 11:12 |
 |
Articles in Press |
|
2026-01-08 11:12 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345